globenewswire.com

Regeneron Faces Securities Fraud Class Action Over Alleged Misleading Statements

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals
Sig1.70Sen-4.20Env0.00Soc0.00Gov-4.80

Shareholders who bought Regeneron (REGN) shares during the class period are urged to seek lead plaintiff roles in a securities fraud class action. The complaint alleges the company made false and materially misleading statements based on flawed statistical assumptions and that investors suffered damages when the truth emerged. The class is not yet certified, and the suit cites Exchange Act §§10(b) and 20(a) and Rule 10b-5.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro